Involvement of the efflux pumps in chloramphenicol selected strains of Burkholderia thailandensis: Proteomic and mechanistic evidence

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Biot, Fabrice V ^a,b   Valade, Eric ^a,b   Garnotel, Eric ^a,c   Chevalier, Jacqueline ^a   Villard, Claude ^d   Thibault, François M ^a,b   Vidal, Dominique R ^a,b   Pagès, Jean Marie ^a  

^a Aix Marseille University   (France)

^b INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^c LAVERAN MILITARY TEACHING HOSPITAL   (France)

^d University of the Mediterranean Aix Marseille II   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM DERIVATIVE; CEFOXITIN; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLOXACILLIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; NALIDIXIC ACID; NORFLOXACIN; OXACILLIN; PIPERACILLIN; PIPERACILLIN DERIVATIVE; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; TRIMETHOPRIM DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BURKHOLDERIA; BURKHOLDERIA THAILANDENSIS; EFFLUX PUMP; GENE OVEREXPRESSION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PROTEOMICS; CELL MEMBRANE; CYTOLOGY; DRUG EFFECT; GENE; GENETICS; METABOLISM; MUTATION;

BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; BURKHOLDERIA THAILANDENSIS;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA; CELL MEMBRANE; CHLORAMPHENICOL; DRUG RESISTANCE, MULTIPLE; GENES, MDR; MUTATION; PROTEOMICS;

EID: 79951840457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016892     Document Type: Article

References (39)

1. Brett PJ, DeShazer D, Woods DE, (1998) Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int J Syst Bacteriol 48 (Pt 1): 317-320.
2. Glass MB, Gee JE, Steigerwalt AG, Cavuoti D, Barton T, et al. (2006) Pneumonia and septicemia caused by Burkholderia thailandensis in the United States. J Clin Microbiol 44: 4601-4604.
3. Kim HS, Schell MA, Yu Y, Ulrich RL, Sarria SH, et al. (2005) Bacterial genome adaptation to niches: divergence of the potential virulence genes in three Burkholderia species of different survival strategies. BMC Genomics 6: 174.
4. Yu Y, Kim HS, Chua HH, Lin CH, Sim SH, et al. (2006) Genomic patterns of pathogen evolution revealed by comparison of Burkholderia pseudomallei, the causative agent of melioidosis, to avirulent Burkholderia thailandensis. BMC Microbiol 6: 46.
5. White NJ, (2003) Melioidosis. Lancet 361: 1715-1722.
6. Chaowagul W, Chierakul W, Simpson AJ, Short JM, Stepniewska K, et al. (2005) Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother 49: 4020-4025.
7. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD, (2004) Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 54: 1134-1138.
8. Estes DM, Dow SW, Schweizer HP, Torres AG, (2010) Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther 8: 325-338.
9. Jenney AW, Lum G, Fisher DA, Currie BJ, (2001) Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 17: 109-113.
10. Dance DA, Wuthiekanun V, Chaowagul W, White NJ, (1989) The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother 24: 295-309.
11. Godfrey AJ, Wong S, Dance DA, Chaowagul W, Bryan LE, (1991) Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase. Antimicrob Agents Chemother 35: 1635-1640.
12. Ong C, Ooi CH, Wang D, Chong H, Ng KC, et al. (2004) Patterns of large-scale genomic variation in virulent and avirulent Burkholderia species. Genome Res 14: 2295-2307.
13. Chan YY, Tan TM, Ong YM, Chua KL, (2004) BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei. Antimicrob Agents Chemother 48: 1128-1135.
14. Kumar A, Chua KL, Schweizer HP, (2006) Method for regulated expression of single-copy efflux pump genes in a surrogate Pseudomonas aeruginosa strain: identification of the BpeEF-OprC chloramphenicol and trimethoprim efflux pump of Burkholderia pseudomallei 1026b. Antimicrob Agents Chemother 50: 3460-3463.
15. Mima T, Schweizer HP, (2010) The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob Agents Chemother 54: 3113-3120.
16. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE, (1999) Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother 43: 465-470.
17. Trunck LA, Propst KL, Wuthiekanun V, Tuanyok A, Beckstrom-Sternberg SM, et al. (2009) Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl Trop Dis 3: e519.
18. Viktorov DV, Zakharova IB, Podshivalova MV, Kalinkina EV, Merinova OA, et al. (2008) High-level resistance to fluoroquinolones and cephalosporins in Burkholderia pseudomallei and closely related species. Trans R Soc Trop Med Hyg 102 (Suppl 1): S103-110.
19. Thongdee M, Gallagher LA, Schell M, Dharakul T, Songsivilai S, et al. (2008) Targeted mutagenesis of Burkholderia thailandensis and Burkholderia pseudomallei through natural transformation of PCR fragments. Appl Environ Microbiol 74: 2985-2989.
20. Okusu H, Ma D, Nikaido H, (1996) AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol 178: 306-308.
21. Pradel E, Pages JM, (2002) The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes. Antimicrob Agents Chemother 46: 2640-2643.
22. Ghisalberti D, Masi M, Pages JM, Chevalier J, (2005) Chloramphenicol and expression of multidrug efflux pump in Enterobacter aerogenes. Biochem Biophys Res Commun 328: 1113-1118.
23. McMurry LM, George AM, Levy SB, (1994) Active efflux of chloramphenicol in susceptible Escherichia coli strains and in multiple-antibiotic-resistant (Mar) mutants. Antimicrob Agents Chemother 38: 542-546.
24. Davin-Regli A, Bolla JM, James CE, Lavigne JP, Chevalier J, et al. (2008) Membrane permeability and regulation of drug "influx and efflux" in enterobacterial pathogens. Curr Drug Targets 9: 750-759.
25. Mamelli L, Petit S, Chevalier J, Giglione C, Lieutaud A, et al. (2009) New antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitors. PLoS One 4: e6443.
26. Vaara M, (1992) Agents that increase the permeability of the outer membrane. Microbiol Rev 56: 395-411.
27. Nikaido H, (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67: 593-656.
28. Pages JM, Amaral L, (2009) Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta 1794: 826-833.
29. Pages JM, Lavigne JP, Leflon-Guibout V, Marcon E, Bert F, et al. (2009) Efflux pump, the masked side of beta-lactam resistance in Klebsiella pneumoniae clinical isolates. PLoS One 4: e4817.
30. Li XZ, Nikaido H, Poole K, (1995) Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother 39: 1948-1953.
31. Bornet C, Chollet R, Mallea M, Chevalier J, Davin-Regli A, et al. (2003) Imipenem and expression of multidrug efflux pump in Enterobacter aerogenes. Biochem Biophys Res Commun 301: 985-990.
32. Poole K, (2004) Efflux-mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect 10: 12-26.
33. Chevalier J, Mahamoud A, Baitiche M, Adam E, Viveiros M, et al. (2010) Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains. Int J Antimicrob Agents 36: 164-168.
34. Schweizer HP, (2003) Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet Mol Res 2: 48-62.
35. Mima T, Schweizer HP, Xu ZQ, (2010) In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance. J Antimicrob Chemother. [Epub ahead of print] 2010 Oct 21.
36. Yoshihara E, Eda S, Kaitou S, (2009) Functional interaction sites of OprM with MexAB in the Pseudomonas aeruginosa multidrug efflux pump. FEMS Microbiol Lett 299: 200-204.
37. Kumar A, Mayo M, Trunck LA, Cheng AC, Currie BJ, et al. (2008) Expression of resistance-nodulation-cell-division efflux pumps in commonly used Burkholderia pseudomallei strains and clinical isolates from northern Australia. Trans R Soc Trop Med Hyg 102 (Suppl 1): S145-151.
38. Mallea M, Chevalier J, Bornet C, Eyraud A, Davin-Regli A, et al. (1998) Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiology 144 (Pt 11): 3003-3009.
39. Chevalier J, Bredin J, Mahamoud A, Mallea M, Barbe J, et al. (2004) Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob Agents Chemother 48: 1043-1046.